dc.contributor.author | Laajala, Mira | |
dc.contributor.author | Kalander, Kerttu | |
dc.contributor.author | Consalvi, Sara | |
dc.contributor.author | Amamuddy, Olivier Sheik | |
dc.contributor.author | Bishop, Özlem Tastan | |
dc.contributor.author | Biava, Mariangela | |
dc.contributor.author | Poce, Giovanna | |
dc.contributor.author | Marjomäki, Varpu | |
dc.date.accessioned | 2023-03-28T09:35:25Z | |
dc.date.available | 2023-03-28T09:35:25Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Laajala, M., Kalander, K., Consalvi, S., Amamuddy, O. S., Bishop, Ö. T., Biava, M., Poce, G., & Marjomäki, V. (2023). Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9. <i>Pharmaceutics</i>, <i>15</i>(3), Article 1028. <a href="https://doi.org/10.3390/pharmaceutics15031028" target="_blank">https://doi.org/10.3390/pharmaceutics15031028</a> | |
dc.identifier.other | CONVID_182306817 | |
dc.identifier.uri | https://jyx.jyu.fi/handle/123456789/86147 | |
dc.description.abstract | Enteroviruses are one of the most abundant groups of viruses infecting humans, and yet there are no approved antivirals against them. To find effective antiviral compounds against enterovirus B group viruses, an in-house chemical library was screened. The most effective compounds against Coxsackieviruses B3 (CVB3) and A9 (CVA9) were CL212 and CL213, two N-phenyl benzamides. Both compounds were more effective against CVA9 and CL213 gave a better EC50 value of 1 µM with high a specificity index of 140. Both drugs were most effective when incubated directly with viruses suggesting that they mainly bound to the virions. A real-time uncoating assay showed that the compounds stabilized the virions and radioactive sucrose gradient as well as TEM confirmed that the viruses stayed intact. A docking assay, taking into account larger areas around the 2-and 3-fold axes of CVA9 and CVB3, suggested that the hydrophobic pocket gives the strongest binding to CVA9 but revealed another binding site around the 3-fold axis which could contribute to the binding of the compounds. Together, our data support a direct antiviral mechanism against the virus capsid and suggest that the compounds bind to the hydrophobic pocket and 3-fold axis area resulting in the stabilization of the virion. | en |
dc.format.mimetype | application/pdf | |
dc.language.iso | eng | |
dc.publisher | MDPI AG | |
dc.relation.ispartofseries | Pharmaceutics | |
dc.rights | CC BY 4.0 | |
dc.subject.other | enterovirus | |
dc.subject.other | antiviral | |
dc.subject.other | capsid binder | |
dc.subject.other | N-phenyl benzamide | |
dc.title | Antiviral Mechanisms of N-Phenyl Benzamides on Coxsackie Virus A9 | |
dc.type | research article | |
dc.identifier.urn | URN:NBN:fi:jyu-202303282287 | |
dc.contributor.laitos | Bio- ja ympäristötieteiden laitos | fi |
dc.contributor.laitos | Department of Biological and Environmental Science | en |
dc.contributor.oppiaine | Solu- ja molekyylibiologia | fi |
dc.contributor.oppiaine | Nanoscience Center | fi |
dc.contributor.oppiaine | Cell and Molecular Biology | en |
dc.contributor.oppiaine | Nanoscience Center | en |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | |
dc.description.reviewstatus | peerReviewed | |
dc.relation.issn | 1999-4923 | |
dc.relation.numberinseries | 3 | |
dc.relation.volume | 15 | |
dc.type.version | publishedVersion | |
dc.rights.copyright | © 2023 by the authors. Licensee MDPI, Basel, Switzerland | |
dc.rights.accesslevel | openAccess | fi |
dc.type.publication | article | |
dc.relation.grantnumber | 336487 | |
dc.subject.yso | kapsidi | |
dc.subject.yso | tartuntataudit | |
dc.subject.yso | enterovirukset | |
dc.subject.yso | virukset | |
dc.format.content | fulltext | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p28020 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p1804 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p20689 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p1123 | |
dc.rights.url | https://creativecommons.org/licenses/by/4.0/ | |
dc.relation.doi | 10.3390/pharmaceutics15031028 | |
dc.relation.funder | Research Council of Finland | en |
dc.relation.funder | Suomen Akatemia | fi |
jyx.fundingprogram | Others, AoF | en |
jyx.fundingprogram | Muut, SA | fi |
jyx.fundinginformation | This work was supported by Jane and Aatos Erkko Foundation and Academy of Finland (#336487). | |
dc.type.okm | A1 | |